Ask the Experts
- ACE inhibitors: Usual doses may be too low to lower morbidity, death. Leibovitch, Eric R. // Geriatrics;Mar97, Vol. 52 Issue 3, p76
Presents an abstract of the article `Do Angiotensin-Converting Enzyme Inhibitors Prolong Life in Patients with Heart Failure Treated in Clinical Practice?' by M. Packer published in the `Journal of the American College of Cardiology' dated 1996.
- Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. Clark, A.L.; Coats, A.J.S. // BMJ: British Medical Journal (International Edition);4/15/95, Vol. 310 Issue 6985, p973
Studies the uses of angiotensin converting enzyme inhibitors for chronic heart failure in a tertiary referral center. Investigation of the relation between the regimen used and patient variables and how this related to the dosages.
- Stick with highest ACE inhibitor dose. // Pulse;5/25/2011, Vol. 71 Issue 19, p9
The article offers information on the efficiency of low-dose angiotensin converting enzyme (ACE) inhibitors in heart failure with recommendations of titration and blood pressure monitoring.
- Trial confirms efficacy of high-dose ACE inhibitors for CHF. Lucas, Beverly D. // Patient Care;1/15/2000, Vol. 34 Issue 1, p8
Presents the findings of the Assessment of Treatment with Lisinopril and Survival study on the efficacy of high-dose angiotensin-converting enzyme (ACE) inhibitors for the treatment of congestive heart failure. Risks associated with high- and low-dose lisinopril; Adverse effects manifested by...
- Implications of EMPHASIS-HF for Clinical Practice. Pfeffer, Marc; Pitt, Bertram; Zannad, Faiez // Medical Roundtable: Cardiovascular Edition;Winter2011, Vol. 2 Issue 1, p7
The discussion focused primarily on: (1) the RALES trial, (2) effects of combining spironolactone and ACE inhibtors on renal function, (3) the CONSENSUS trial, (4) US physician concern over use of spironolactone and hyperkalemia, (5) European experience with effective spironolactone therapy, (6)...
- ACE inhibitors remain first choice in the treatment of heart failure. // Geriatrics;Dec99, Vol. 54 Issue 12, p62
Reports on the effectivity of angiotensin converting enzyme (ACE) inhibitor as heart failure therapy. Comparison of the effects of ACE inhibitor captopril and angiotensin II receptor antagonist (AIIRA) losartan on mortality among older patients with heart failure; Rates of hospitalization for...
- Mild heart failure: Why the switch to ACE inhibitors. Khosla, Sandeep; Somberg, John // Geriatrics;Nov93, Vol. 48 Issue 11, p47
Discusses the benefits of angiotensin-converting enzyme (ACE) inhibitor therapy in patients with mild congestive heart failure (CHF). Mechanisms of ACE inhibitors; Common causes of CHF; Dosing strategy.
- Consider ACE inhibitors for all CHF patients, even the very old and frail. // Geriatrics;Mar2000, Vol. 55 Issue 3, p95
Presents information on a study which examined the effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. Methodology of the study; Results and discussion on the study.
- 547 Long-term combined therapy of ACe inhibitor quinapril and ARB valsartan have not additional beneficial effect on HRV parameters compared to monotherapy with either quinapril or valsartan in CHF. Skvortsov, A.; Nasonov, S.; Arbolishvili, G.; Sychev, A.; Baklanova, N.; Mareev, V.; Belenkov, Y. // European Journal of Heart Failure. Supplements;Jun2006, Vol. 5 Issue 1, p121
An abstract of the study "Long-Term Combined Therapy of ACE Inhibitor Quinapril and ARB Valsartan Have Not Additional Beneficial Effect on HRV Parameters Compared to Monotherapy With Either Quinapril or Valsartan in CHF," by A. Skvortsov and colleagues is presented.